Business Insider

Neurelis Announces 16 Poster Presentations at the Annual Meeting of the American Epilepsy Society

SAN DIEGO, Dec. 2, 2021 /PRNewswire/ -- Neurelis, Inc. will present a collection of 16 posters describing safety, tolerability and effectiveness results observed in trials evaluating VALTOCO ® ...
Yahoo Finance

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...
Business Wire

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet ...

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy ...
Yahoo Finance

Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings

CHESTERBROOK, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ...
Medindia

UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology

ATLANTA, April 18, 2012 /PRNewswire/ -- UCB, a leading biopharmaceutical company committed to the development of new epilepsy treatments and research, will sponsor multiple sets of key epilepsy data ...
Morningstar

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International ...

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress – 3-year ...
Business Insider

NEURELIS ANNOUNCES PRESENTATIONS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

New analyses from phase 3, long-term, open-label, repeat-dose study of VALTOCO ® (diazepam nasal spray) CIV will be presented Additional presentations explore anticipatory anxiety of seizures, ...